Business Description
Antibiotice SA
ISIN : ROATBIACNOR9
Total Employee Number:
1,356Compare
Compare
Traded in other countries / regions
ATB.Romania0DMW.UK IPO Date
2007-10-27Description
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.33 | |||||
Debt-to-EBITDA | 3.22 | |||||
Interest Coverage | 9.06 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.54 | |||||
Beneish M-Score | -2.34 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.1 | |||||
3-Year EBITDA Growth Rate | 7.7 | |||||
3-Year EPS without NRI Growth Rate | -6.4 | |||||
3-Year Book Growth Rate | 7.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.83 | |||||
Quick Ratio | 1.11 | |||||
Cash Ratio | 0.01 | |||||
Days Inventory | 332.83 | |||||
Days Sales Outstanding | 203.97 | |||||
Days Payable | 154.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.55 | |||||
3-Year Dividend Growth Rate | 91.3 | |||||
Shareholder Yield % | -7.08 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.46 | |||||
Operating Margin % | 6.72 | |||||
Net Margin % | 5.11 | |||||
EBITDA Margin % | 15.55 | |||||
FCF Margin % | -17.95 | |||||
OCF Margin % | 10.62 | |||||
ROE % | 3.4 | |||||
ROA % | 2.24 | |||||
ROIC % | 2.8 | |||||
3-Year ROIIC % | -0.88 | |||||
ROC (Joel Greenblatt) % | 3.48 | |||||
ROCE % | 3.65 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 46.38 | |||||
PE Ratio without NRI | 57.37 | |||||
Shiller PE Ratio | 26.51 | |||||
PEG Ratio | 2.6 | |||||
PS Ratio | 2.36 | |||||
PB Ratio | 1.55 | |||||
Price-to-Tangible-Book | 1.68 | |||||
Price-to-Operating-Cash-Flow | 22.24 | |||||
EV-to-EBIT | 42.22 | |||||
EV-to-EBITDA | 18.36 | |||||
EV-to-Revenue | 2.86 | |||||
EV-to-FCF | -15.91 | |||||
Price-to-GF-Value | 0.99 | |||||
Price-to-Projected-FCF | 2.02 | |||||
Price-to-DCF (Earnings Based) | 0.48 | |||||
Price-to-Median-PS-Value | 2.3 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.81 | |||||
Price-to-Graham-Number | 2.11 | |||||
| Price-to-Net-Current-Asset-Value | 50.54 | |||||
Earnings Yield (Greenblatt) % | 2.37 | |||||
FCF Yield % | -7.61 | |||||
Forward Rate of Return (Yacktman) % | 19.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Antibiotice SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil lei) | 620.692 | ||
| EPS (TTM) (lei) | 0.047 | ||
| Beta | -0.1597 | ||
| 3-Year Sharpe Ratio | -54.52 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | 4.07 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (lei) | - | ||
| 20-Day SMA (lei) | 0.5054 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (lei) | 0.5054 - 0.5054 | ||
| Shares Outstanding (Mil) | 671.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Antibiotice SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Antibiotice SA Stock Events
| Event | Date | Price (lei) | ||
|---|---|---|---|---|
| RON 0.020557 Cash Dividend | 2025-09-25 | 0.51 (+0.00%) | ||
| RON 0.082923 Cash Dividend | 2024-09-23 | 0.51 (+0.00%) | ||
| 1.18915:1 Stock Split | 2011-05-12 | 0.56 (+0.00%) | ||
| 1.05003:1 Stock Split | 2010-11-25 | 0.53 (+0.00%) |
Show
Entries
Antibiotice SA Frequently Asked Questions
What is Antibiotice SA(LTS:0DMW)'s stock price today?
The current price of LTS:0DMW is lei0.51. The 52 week high of LTS:0DMW is lei0.51 and 52 week low is lei0.51.
When is next earnings date of Antibiotice SA(LTS:0DMW)?
The next earnings date of Antibiotice SA(LTS:0DMW) is .
Does Antibiotice SA(LTS:0DMW) pay dividends? If so, how much?
Antibiotice SA(LTS:0DMW) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Antibiotice SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers